The following is a summary of the Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Theravance Biopharma reported Q1 net sales of $55.2 million in partnership with Viatris, marking an 18% growth year-on-year.

• The company ended the quarter with $100 million in cash and no debt, indicating a strong financial position.

• The company is targeting a one-time sales milestone of $25 million from Viatris when YUPELRI net sales hit $250 million in a calendar year.

Business Progress:

• YUPELRI, the company's main product, saw a significant 31% increase in hospital doses sold compared to the prior year.

• Regulatory filing for YUPELRI in China is planned to be completed by Viatris by the middle of the year based on compelling Phase 3 results.

• Completion of Phase 3 CYPRESS study for Ampreloxetine is projected to be achieved in the second half of the year.

• The company anticipates YUPELRI to continue contributing significantly to business growth and value creation.

• The company is focused on achieving potential milestones with its trilogy project, which may bolster its profitability.

• Theravance expects a $7.5 million milestone payment upon the approval of the China equivalent of an NDA.

• The company is upbeat about the Ampreloxetine data from CYPRESS and the results of the trilogy project, aiming to reach milestones that could amount to $200 million by 2026.

• The company is planning to host an investor event on May 23rd to review all data on MSA, nOH, and Ampreloxetine and to discuss the company's opportunities and potential patient benefits.

More details: Theravance Biopharma IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.